Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection

A randomized, open-label, multicenter study to establish clinical equivalence (non-inferiority) of a regimen employing a lamivudine 150 mg/zidovudine 300 mg combination tablet, administered twice daily, plus a marketed protease inhibitor, compared with a conventional regimen of 150 mg lamivudine twi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	AIDS (London) 2000-04, Vol.14 (6), p.671-681
Hauptverfasser:	Eron, J J, Yetzer, E S, Ruane, P J, Becker, S, Sawyer, G A, Fisher, R L, Tolson, J M, Shaefer, M S
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged AIDS/HIV Anti-HIV Agents - administration & dosage Anti-HIV Agents - therapeutic use CD4 Lymphocyte Count Drug Combinations Drug Therapy, Combination Female HIV Infections - drug therapy HIV Infections - virology HIV Protease Inhibitors - administration & dosage HIV Protease Inhibitors - therapeutic use HIV-1 - physiology Human immunodeficiency virus 1 Humans Lamivudine - administration & dosage Lamivudine - therapeutic use Male Middle Aged nucleoside analogs Patient Compliance Reverse Transcriptase Inhibitors - therapeutic use RNA, Viral - blood Treatment Outcome Viral Load Zidovudine - administration & dosage Zidovudine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!